Clinical Trial Update: Safety Study in Outpatient Japanese Children With ADHD [Phase 2]

View source ↗

Summary

This document reports the completion of a Phase 2 safety study of atomoxetine (Strattera) for ADHD in outpatient Japanese children, sponsored by Eli Lilly.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• STRATTERA (Atomoxetine hydrochloride)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Attention Deficit Hyperactivity Disorder | Phase 2 | Status: COMPLETED